Biotech Firms Race to Reverse Ageing, Targeting Longevity Market

Targeting US$610 billion longevity market, biotech firms race to reverse ageing

For Beijing-based METiS TechBio CEO Lai Tsai-ta, ageing is comparable to bugs building up in a complex software system – it happens once errors begin to accumulate in the genetic code of human cells, such as their DNA sequences. “Those errors can be reprogrammed. It becomes possible to use AI to read, rewrite and reverse cells, or at least slow the ageing process,” Lai said in an interview with the South China Morning Post. The process could begin by fixing “immune cells, such as T cells, as...

By Julie Zhang